Receive Our Newsletter

Catalyst Biosciences Completes New Hemophilia B Drug Toxicology Study

industry_news_banner

On April 11, Catalyst Biosciences, a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, reached a key milestone towards starting human trials with completion of the CB 2679d/ISU304 toxicology studies. Their press release can be read in full here.

Comments (No comments)

Assisting and Advocating for the Bleeding Disorders Community